Transvaginal Mesh — 100,000 Lawsuits, $8 Billion, and a 2019 U.S. Ban

When the U.S. Food and Drug Administration ordered Boston Scientific and Coloplast on April 16, 2019 to stop selling all surgical mesh intended for transvaginal repair of pelvic organ prolapse, the gap between the promise and the harm was already a settled scientific finding: the agency stated the manufacturers had “not demonstrated a reasonable assurance of safety and effectiveness,” having “failed to demonstrate an acceptable long-term benefit of these devices compared to transvaginal surgical tissue repair without the use of mesh.” The mesh had been sold for nearly two decades as a stronger, more durable fix for sagging pelvic organs. The controlled evidence showed it was no better than stitching native tissue — and considerably more dangerous.

The product was a knitted sheet of non-absorbable polypropylene, placed through the vagina to act as a hammock under a prolapsed bladder, uterus or rectum. Its central failure mode was that the implant did not stay inert. Over months and years the mesh contracted, hardened and eroded through the vaginal wall and into adjacent organs, producing a signature cluster of harms: chronic pelvic pain, dyspareunia (painful intercourse), bleeding, infection, urinary problems, organ perforation, and erosion that frequently could not be fully reversed because the mesh integrated into tissue and fragmented on removal. The FDA’s own reviews put serious complications well above the “rare” reassurance physicians had been given.

The devices reached the market not through clinical proof but through the 510(k) clearance pathway, which lets a manufacturer skip pre-market testing by claiming “substantial equivalence” to an existing product — in this case an older abdominal hernia mesh and the first transvaginal kits, each in turn cleared by pointing back to a predecessor. No randomized trial of safety and effectiveness was ever required to put these implants into women. The reckoning came in two channels at once. Litigation consolidated into one of the largest mass-tort proceedings in U.S. history — more than 100,000 lawsuits against Ethicon (Johnson & Johnson), Boston Scientific, American Medical Systems, C.R. Bard, Coloplast and others, resolved for upward of $8 billion. Regulation moved more slowly: a 2008 public-health notification, a blunt 2011 reversal (“not rare”), reclassification to Class III in January 2016, and finally the 2019 stop-sale order when no maker could produce the safety data the new class demanded. Transvaginal POP mesh became the textbook case of a permanent implant cleared without proof and withdrawn only after the evidence — and the bodies — caught up.